filmov
tv
Overview of the Therapeutic Landscape for Angelman Syndrome
Показать описание
Allyson Berent, DVM, DACVIM, Chief Science Officer for FAST, gives an overview of FAST's mission and vision through an aggressive drug development roadmap. She lays out FAST's robust efforts involving deep collaboration with academic, industry and regulatory partners and shares an overview of the current therapeutic landscape for Angelman syndrome.
Disclaimer: The information contained in these slides and video is provided for informational purposes only and should not be construed as medical, legal, financial, or any other type of professional advice. The content is subject to change without notice and is not intended to be relied upon as definitive guidance. The information contained was accurate as of the date of preparation; however, please note that some data, facts and figures may have changed or become outdated if reviewed after the presentation date. FAST makes no commitment to update this content and advises viewers to verify information for its current relevance.
These slides and video and all associated intellectual property are the exclusive property of the Foundation for Angelman Syndrome Therapeutics. Unauthorized modification, reproduction, translation, or distribution of any part of these slides and video is strictly prohibited.
Disclaimer: The information contained in these slides and video is provided for informational purposes only and should not be construed as medical, legal, financial, or any other type of professional advice. The content is subject to change without notice and is not intended to be relied upon as definitive guidance. The information contained was accurate as of the date of preparation; however, please note that some data, facts and figures may have changed or become outdated if reviewed after the presentation date. FAST makes no commitment to update this content and advises viewers to verify information for its current relevance.
These slides and video and all associated intellectual property are the exclusive property of the Foundation for Angelman Syndrome Therapeutics. Unauthorized modification, reproduction, translation, or distribution of any part of these slides and video is strictly prohibited.